340B Insight wants to make our podcast the best it can be. To help us succeed, we’d like to hear your thoughts. Please take just a few minutes to complete our listener survey, and we will enter you in a drawing to win a $100 gift card! To participate, please go to 340bpodcast.org/survey.

This week, we are joined by Paul Mollo, national director of medication outcomes disparity at Ascension. Paul discusses what skills and professional backgrounds hospitals consider when building a team to operate their 340B programs and ensure compliance. He also shares overall 340B staffing trends. Before the interview, our news update covers the appointment of a new HRSA Office of Pharmacy Affairs director. 

340B Team Structure 

Paul explains how Ascension’s 340B team is structured at the national, regional, and local levels, as well as staffing models at other 340B hospitals. Under his leadership, Ascension has created a method for determining when the 340B team is sufficiently staffed. 

The Skills 340B Professionals Need 

Paul discusses the importance of hiring 340B professionals who are mission-oriented and come from a variety of career and educational backgrounds. He emphasizes the importance of building a 340B team where individuals complement each other’s strengths. 

The Future of 340B Staffing 

340B teams have changed since the start of the program. Paul shares how 340B teams have evolved to incorporate technology, and he analyzes what the next big trend in 340B staffing will be.

Check out all of our episodes on the 340B Insight podcast website. You also can stay updated on all 340B Health news and information by visiting our homepage. If you have any questions you’d like us to cover in this podcast, email us at [email protected].

Resources 

1. 340B Health Statement on New Director of HRSA Office of Pharmacy Affairs
2. 340B Health Letter to HHS Leadership on March 1 Regarding Contract Pharmacy Claims Data Submission Concerns 
3. 340B Health Letter to AbbVie CEO Regarding Contract Pharmacy Restrictions 
4. 340B Health Letter to Bristol Myers Squibb CEO Regarding Contract Pharmacy Restrictions